NCT05620836已完成3 期
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 619
- 试验地点
- 202
- 主要终点
- Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female participants ≥ 18 years of age.
- •Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.
- •HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits.
- •Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits.
- •History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS)
- •Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period.
- •Willingness to avoid pregnancy or fathering children.
- •Other inclusion criteria apply.
排除标准
- •Draining tunnel count of > 20 at Screening or Baseline visits.
- •Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- •Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
- •Evidence of infection with TB, HBV, HCV or HIV.
- •History of failure to JAK inhibitor treatment of any inflammatory disease.
- •Laboratory values outside of the protocol-defined ranges.
- •Other exclusion criteria apply.
研究组 & 干预措施
Povorcitinib Dose A
Experimental
Participants will receive Povorcitinib Dose A for 54 weeks.
干预措施: Povorcitinib (Drug)
Povorcitinib Dose B
Experimental
Participants will receive Povorcitinib Dose B for 54 weeks.
干预措施: Povorcitinib (Drug)
Placebo
Placebo Comparator
Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)
时间窗: Week 12
HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.
次要结局
- Mean change from baseline in Dermatology Life Quality Index (DLQI) score(54 weeks)
- Extension Period: Proportion of participants who achieve HiSCR(Week 54)
- Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)(Week 12)
- Proportion of participants with flare(12 Weeks)
- Proportion of participants with a ≥ 3-point decrease in Skin Pain Numeric Rating Scale (NRS) score among participants with baseline Skin Pain NRS score ≥ 3(Week 12)
- Proportion of participants who achieve Skin Pain NRS30 at Week 12 among participants with baseline Skin Pain NRS score ≥ 3.(Week 12)
- Proportion of participants with a ≥ 4-point increase from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score(Week 12)
- Mean change from baseline in abscess count(54 weeks)
- Mean change from baseline in draining tunnel count(54 weeks)
- Percentage change from baseline in draining tunnel count(54 weeks)
- Extension Period: Proportion of participants who achieve HiSCR75(Week 54)
- Percentage change from baseline in abscess count(54 weeks)
- Mean change from baseline in inflammatory nodule count(54 weeks)
- Percentage change from baseline in inflammatory nodule count(54 weeks)
- Extension Period: Proportion of participants with flare(From Week 12 through Week 54)
- Extension Period: Proportion of participants who achieved Skin Pain NRS30 among participants with baseline Skin Pain NRS score ≥ 3.(Week 54)
- Extension Period: Proportion of participants who achieve maintenance of HiSCR or greater response at each visit(From Week 12 through Week 54)
- Extension Period: Proportion of participants who achieve maintenance of HiSCR75 or greater response at each visit(From Week 12 through Week 54)
- Extension Period: Proportion of participants who achieve HiSCR(Week 24)
- Extension Period: Proportion of participants who achieve HiSCR75(Week 24)
- Extension Period: Proportion of participants with flare(From Week 12 through Week 24)
- Extension Period: Proportion of participants who achieved Skin Pain NRS30 among participants with baseline Skin Pain NRS score ≥ 3.(Week 24)
研究者
研究点 (202)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativa (HS)NCT05620823Incyte Corporation608
进行中（未招募）
3 期
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)NonSegmental VitiligoNCT06113471Incyte Corporation450
进行中（未招募）
3 期
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)NonSegmental VitiligoNCT06113445Incyte Corporation467
进行中（未招募）
3 期
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisUveitisNCT06431373Priovant Therapeutics, Inc.371
进行中（未招募）
3 期
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativa (HS)NCT06212999Incyte Corporation617